Raymond James analyst Laura Prendergast initiated coverage of Third Harmonic Bio with an Outperform rating and $18 price target. Third Harmonic is well positioned to have a second mover advantage in the incredibly large mast cell disease market, and its broad market opportunity is estimated at roughly $26B, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THRD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue